纳武利尤单抗单药及联合安罗替尼治疗老年晚期胃癌患者的效果
CSTR:
作者:
作者单位:

(徐州市肿瘤医院·徐州市第三人民医院药剂科,江苏 徐州 221005)

作者简介:

通讯作者:

中图分类号:

基金项目:

江苏大学医教协同创新基金(JDYY2023047)


Effect of nivolumab alone and combined with anlotinib in treatment of elderly patients with advanced gastric cancer
Author:
Affiliation:

(Department of Pharmacy, Xuzhou Cancer Hospital, Xuzhou Third People′s Hospital, Xuzhou 221005, Jiangsu Province, China)

Fund Project:

This work was supported by the Medical Education Collaborative Innovation Fund of Jiangsu University (JDYY2023047).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 探讨纳武利尤单抗联合安罗替尼治疗老年晚期胃癌的效果。方法 选择徐州市肿瘤医院2021年1月至2023年1月收治的120例接受三线治疗的老年晚期胃癌患者为研究对象,其中60例患者接受纳武利尤单抗治疗(单药治疗组),另外60例患者接受纳武利尤单抗联合安罗替尼治疗(联合治疗组)。两组患者均连续治疗4个疗程,统计治疗后客观缓解率(ORR)及疾病控制率(DCR),检测治疗前后血管内皮生长因子A(VEGF-A)、癌胚蛋白(CEA)、基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)及外周血T淋巴细胞亚群水平,统计不良反应发生情况。采用SPSS 22.0统计软件进行数据分析,根据数据类型分别采用t检验或χ2检验进行组间比较。采用Kaplan-Meier法分析各组病例累积生存率,采用Log-rank检验分析两组患者的生存差异性。结果 联合治疗组DCR及ORR分别为76.67%(46/60)和43.33%(26/60),均高于单药治疗组[58.33%(35/60)和25.00%(15/60)],差异均有统计学意义(P<0.05)。联合治疗组治疗后血清VEGF-A、CEA、MMP-2及MMP-9水平均低于单药治疗组;CD3+、CD4+、CD4+/CD8+水平高于单药治疗组,CD8+水平低于单药治疗组,差异均有统计学意义(P<0.05)。联合治疗组与单药治疗组不良反应发生情况比较,差异无统计学意义(P>0.05)。随访至2024年2月,结果显示联合治疗组及单药治疗组中位无进展生存时间(PFS)分别为6.10个月(95%CI 4.607~7.593)与4.00个月(95%CI 3.059~4.941);中位总生存时间(OS)分别为9.25个月(95%CI 8.394~10.099)与6.19个月(95%CI 5.583~6.789),差异均有统计学意义(χ2=6.298、4.943,P<0.05)。结论 纳武利尤单抗联合安罗替尼作为老年晚期胃癌患者的三线治疗方案能有效延长患者生存时间,提高肿瘤控制效果,但其疗效需进一步开展多中心、大样本量的前瞻性研究进行验证。

    Abstract:

    Objective To explore the effect of nivolumab combined with anlotinib in the treatment of elderly advanced gastric cancer. Methods A total of 120 elderly patients with advanced gastric cancer who received third-line treatment in our hospital from January 2021 to January 2023 were enrolled, and 60 of them received nivolumab treatment (single drug treatment group), and the other 60 ones received nivolumab combined with anlotinib treatment (combined treatment group). After four continuous courses of treatment, the objective remission rate (ORR) and disease control rate (DCR) were calculated. The peripheral blood levels of vascular endothelial growth factor A (VEGF-A), carcinoembryonic antigen (CEA), matrix metalloproteinase-2 (MMP-2) and MMP-9 and the percentages of peripheral blood T lymphocyte subsets were detected before and after treatment. The occurrence of adverse reactions was observed. SPSS statistics 22.0 was used for data analysis, and t test or Chi-square test was employed for between-group comparison depending on data type. Kaplan-Meier survival analysis was applied to analyze the cumulative survival rate of each group, and Log-rank test was conducted to analyze the difference in survival rate between the two groups. Results The DCR and ORR in the combined treatment group was 76.67% (46/60) and 43.33% (26/60), which were higher than those of the single drug treatment group [58.33% (35/60) and 25.00% (15/60), P<0.05]. After treatment, the combined treatment group had significantly lower serum VEGF-A, CEA, MMP-2 and MMP-9 levels, higher percentages of CD3+, CD4+ T cells and CD4+/CD8+ ratio, but lower percentage CD8+ T cells when compared to the single drug treatment group (P<0.05). There was no statistical difference in occurrence of adverse reactions between the two groups (P>0.05). The patients were followed up until February 2024, and the results showed that in the combined treatment group and single drug treatment group, the median progression-free survival (PFS) was 6.10 months (95%CI 4.607-7.593) and 4.00 months (95%CI 3.059-4.941), and the median overall survival (OS) was 9.25 months (95%CI 8.394-10.099) and 6.19 months (95%CI 5.583-6.789), respectively, with statistical differences between them (χ2=6.298,4.943, P<0.05). Conclusion Nivolumab combined with anlotinib, as a third-line treatment regimen, can effectively prolong the survival time and improve the tumor control effect in elderly patients with advanced gastric cancer. However, its efficacy needs to be further verified by multi-center, large-sample prospective studies.

    参考文献
    相似文献
    引证文献
引用本文

甘钦,刘天龙,李国强.纳武利尤单抗单药及联合安罗替尼治疗老年晚期胃癌患者的效果[J].中华老年多器官疾病杂志,2025,24(6):456-460
DOI:10.11915/j. issn.1671-5403.2025.06.095

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2024-06-14
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-06-25
  • 出版日期:
文章二维码